NASDAQ · Health care

Quoin Pharmaceuticals, Ltd. (QNRX)

It posted a net loss of $18.7M. At June 30, 2026 it held $3.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Price

$6.43

+3.71% on the day · September 25, 2026

52-week range $3.25 to $41.80

Market cap

$12.9M

What Quoin Pharmaceuticals, Ltd. does

Quoin Pharmaceuticals, Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker QNRX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	n/a	-$15.8M	n/a	n/a
2024	n/a	n/a	-$9M	n/a	n/a
2023	n/a	n/a	-$8.7M	n/a	n/a
2022	n/a	n/a	-$9.4M	n/a	n/a
2021	$0	n/a	-$21.5M	-$0.01	n/a
2020	$0	-$4.4M	-$2.1M	-$0.70	-$1.4M

Full financial statements: income, balance sheet and cash flow

Next report expected around October 23, 2026.

Estimated from its filing rhythm: about 71 days after its last report of August 14, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What Quoin Pharmaceuticals, Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 25, 2026
Securities offering prospectus 424B3
September 22, 2026
Preliminary proxy statement PRE 14A
September 22, 2026
Investor disclosure 8-K
September 18, 2026
Shelf registration to sell securities S-3
September 10, 2026
Investor disclosure 8-K
August 28, 2026
Material agreement 8-K
August 20, 2026
Executive or director change 8-K
August 14, 2026
Quarterly results 8-K
August 14, 2026
Quarterly report 10-Q · period to June 30, 2026Net loss of $5.4M.
July 16, 2026
Annual report to shareholders ARS

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 1, 2026. Insider transactions on SEC

Insider trades

What the people running Quoin Pharmaceuticals, Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $280K worth of shares on the open market in the last 90 days and sold none.

Bought (open market)

$280K

last 90 days

Sold

last 90 days

Net bought

57,370

$280K

Date	Insider	What	Shares	Price	Value	Filing
August 31, 2026	Culverwell Anthony JamesDirector	Bought	6,146	$4.88	$30K	Form 4
August 31, 2026	Lawlor Sally BridgetChief Financial Officer	Bought	10,244	$4.88	$50K	Form 4
August 31, 2026	Myers MichaelChief Executive Officer, Director	Bought	20,490	$4.88	$100K	Form 4
August 31, 2026	Carter Denise P.Chief Operating Officer, Director	Bought	20,490	$4.88	$100K	Form 4
August 27, 2026	Culverwell Anthony JamesDirector	Received as pay	31,352	$5.15	$161.5K	Form 4
August 27, 2026	Langer DennisDirector	Received as pay	34,534	$5.15	$177.9K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns QNRX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Ikarian Capital, LLC13G, passive with 1 related filers	12.6%	211,538	February 6, 2026
Stonepine Capital Management, LLC13G, passive with 3 related filers	9.99%	7,594,166	May 15, 2026
Integrated Core Strategies (US) LLC13G, passive with 3 related filers	5.5%	3,850,385	June 2, 2026

Latest filings below 5%: ADAR1 Capital Management GP, LLC 4.9% (May 15, 2026); Woodline Partners LP 4.4% (May 15, 2026); Aberdeen Group plc 4.16% (April 29, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

5 insiders reported holding 182,713 shares in total, about $1.2M at the last price.

Holder	Shares	As of
Langer DennisDirector	56,243	August 27, 2026
Culverwell Anthony JamesDirector	40,364	August 31, 2026
Myers MichaelChief Executive Officer, Director	37,713	August 31, 2026
Carter Denise P.Chief Operating Officer, Director	37,709	August 31, 2026
Lawlor Sally BridgetChief Financial Officer	10,684	August 31, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about QNRX

What does Quoin Pharmaceuticals, Ltd. do?

Quoin Pharmaceuticals, Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker QNRX.

Is Quoin Pharmaceuticals, Ltd. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $18.7M.

When did Quoin Pharmaceuticals, Ltd. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the securities offering prospectus from September 25, 2026.

Similar companies

Compare QNRX with

Compare QNRX with any company

Follow QNRX

Get an email when Quoin Pharmaceuticals, Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Follow QNRX: get an email when it files

Where the numbers come from

Financial figures are the values Quoin Pharmaceuticals, Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.